ProMining Therapeutics
Drug Discovery Platform for Novel Oral Drugs
Company Overview
Snapshot
Founded in November 2011 by Iris Alroy, Ph.D., ProMining Therapeutics operates with over 18,000 employees. The company has secured funding across one round from Pontifax. In December 2012, ProMining Therapeutics announced a collaboration with Roche on diabetes treatment.
Business overview
ProMining Therapeutics Ltd specializes in the discovery and development of novel oral, small-molecule drugs. The company focuses on treatments for cancer, inflammation, chronic pain, and cardiovascular and viral diseases. Its core technology, CavitIIRx, is a proprietary drug-discovery and development platform centered on SH3 domain-mediated protein-protein interactions, which are crucial in various disease mechanisms. ProMining Therapeutics leverages this platform to identify promising drug candidate molecules, build a pipeline of drugs, and accelerate the drug-discovery process within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals.
Strategic signal
In December 2012, ProMining Therapeutics announced a strategic collaboration with Roche to develop diabetes treatments. This partnership signals significant external validation of ProMining's drug discovery platform and its potential to attract major pharmaceutical players, indicating a strong trajectory for its therapeutic pipeline and market relevance.
Company Intelligence Q&A
- What is ProMining Therapeutics' core technology?
- ProMining Therapeutics developed CavitIIRx, a proprietary drug-discovery and development platform focused on SH3 domain-mediated protein-protein interactions, which play a major role in numerous disease mechanisms.
- When was ProMining Therapeutics founded?
- ProMining Therapeutics was founded in November 2011.
- What was a significant partnership for ProMining Therapeutics?
- In December 2012, ProMining Therapeutics teamed up with Roche on diabetes treatment, indicating a strategic collaboration in drug development.
- Who is a key founder of ProMining Therapeutics?
- Iris Alroy, Ph.D. is the CEO & Co-Founder of ProMining Therapeutics.
- What is the primary focus of ProMining Therapeutics' drug development?
- ProMining Therapeutics focuses on discovering and developing novel oral, small-molecule drugs for the treatment of cancer, inflammation, chronic pain, and cardiovascular and viral diseases.